Advertisement

Topics

VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs

03:00 EDT 17 May 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Valneva Reports Strong Q1 Results and Continues to Advance Key R&D Programs Strong sales and EBITDA performance in Q1 2018 Product sales of €28.9 million in Q1 2018, representing 11.5% year on year growth, in line with Company guidance of d...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Vaccines
A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies. It creates immunity but does not cause the disease. There are several differnt types of vaccine avalable; Killed microorganisms; which s...